Ildong Pharmaceutical Co., Ltd. Stock price

Equities

A249420

KR7249420001

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
16,050 KRW -1.53% Intraday chart for Ildong Pharmaceutical Co., Ltd. +0.19% -11.62%
Sales 2024 * 635B 471M Sales 2025 * 680B 504M Capitalization 448B 332M
Net income 2024 * 31B 22.97M Net income 2025 * 44B 32.6M EV / Sales 2024 * 0.71 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.66 x
P/E ratio 2024 *
14.3 x
P/E ratio 2025 *
10.1 x
Employees 1,166
Yield 2024 *
-
Yield 2025 *
-
Free-Float 60.72%
More Fundamentals * Assessed data
Dynamic Chart
Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea MT
Il Dong Pharmaceutical Introduces New R&D Unit Yunovia MT
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 30 billion in funding CI
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 30 billion in funding CI
Ildong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Il Dong's Application for Shionogi's COVID Oral Medication Accepted for Review in South Korea MT
Ildong Pharmaceutical Co., Ltd. Files a New Drug Application with the MFDS for the Indication of SARS-CoV-2 Infection, and This Application Has Been Accepted for Review by MFDS CI
Shionogi JV Sub-licenses COVID-19 Drug to South Korea's Il Dong Pharmaceutical MT
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology MT
Twist Bioscience Corporation and Ildong Pharmaceutical Enter into Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills MT
Il Dong Pharmaceutical Starts Clinical Trial of COVID-19 Drug MT
Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany CI
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 100 billion in funding CI
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 100 billion in funding CI
More news
1 day-1.53%
1 week+0.19%
Current month+2.23%
1 month+1.20%
3 months-11.62%
6 months-23.57%
Current year-11.62%
More quotes
1 week
15 880.00
Extreme 15880
17 100.00
1 month
15 470.00
Extreme 15470
17 200.00
Current year
15 140.00
Extreme 15140
18 570.00
1 year
14 380.00
Extreme 14380
24 450.00
3 years
12 400.00
Extreme 12400
79 500.00
5 years
9 280.00
Extreme 9280
79 500.00
10 years
9 280.00
Extreme 9280
79 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 16-08-02
Director of Finance/CFO 58 -
Chief Operating Officer 54 -
Members of the board TitleAgeSince
Chief Executive Officer 56 16-08-02
Director/Board Member 62 -
Director of Finance/CFO 58 -
More insiders
Date Price Change Volume
24-03-28 16,050 -1.53% 141,929
24-03-27 16,300 -1.45% 134,080
24-03-26 16,540 -1.90% 157,484
24-03-25 16,860 -0.06% 243,686
24-03-22 16,870 +5.31% 522,939

End-of-day quote Korea S.E., March 27, 2024

More quotes
IL DONG PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Ildong Pharmaceutical Co., Ltd. - Korea S.E.